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<1.8 mcg/L). Physical examination revealed decreased 
visual acuity and decreased hearing bilaterally. She had 
decreased reflexes in the lower extremities bilaterally and 
intact sensation. Lower extremity strength bilaterally was 
limited by pain.
DIFFERENTIAL DIAGNOSIS
Given the patient’s constellation of symptoms and lack 
of other significant past medical history, the differential 
in this case was relatively limited.  The important lesson 
from this case is the need to identify symptoms of cobalt 
toxicity early in patients with prior hip arthroplasty. 
Clinically significant effects of cobalt poisoning rarely 
appear below a whole blood level of 300 mcg/L4.  Above 
this level, patients may begin to develop many of the 
same symptoms displayed here: neurotoxicity including 
optic nerve damage, thyroid toxicity, and fatigue and 
weakness5. Cases of severe cobalt toxicity have even led 
to mortality from worsening dilated cardiomyopathy6.
INTRODUCTION
Patients undergoing total hip arthroplasty represent a 
growing portion of the population.  More than 330,000 
hip replacements are performed annually1, and more than 
2.5 million Americans are living with a hip prosthesis2. 
Many hardware configurations utilize metal alloys for the 
femoral head and/or acetabulum.  Although their use is 
decreasing due to safety concerns, cobalt-chromium 
femoral heads were still used in 51% of total hip arthro-
plasties in 20143.  There is rising concern about the 
adverse effects of metal ions released from these joint 
replacements.  However, little published evidence is 
available supporting specific interventions for the 
management of cobalt toxicity.
Given the increasing incidence and prevalence of total 
hip arthroplasty in the United States, patients with total hip 
replacements will become more commonplace in the 
internist’s practice.  With the risk of adverse effects related 
to these prostheses, it is important to be familiar with the 
presentation of cobalt toxicity in order to spare patients 
from excessive or irreversible damage.
CASE PRESENTATION
The patient is a 61 year-old female with a past medical 
history of total hip arthroplasty in 2004 with a ceramic 
prosthesis who had a cobalt-chromium prosthetic revision 
in May 2015. The old prosthesis was found to be shattered 
during the second operation, and although attempts were 
made to extract all the fragments, it was noted that the 
surgeons were unable to remove all of the particulate 
ceramic debris. Two months later, the patient began 
noticing bilateral hearing loss and blurry vision that 
progressively worsened, as well as peripheral neuropathy 
in her hands and feet. She also developed hypothyroidism 
and was started on levothyroxine. Due to persistent 
abdominal pain, decreased appetite and weight loss, the 
patient had an endoscopy which revealed severe 
gastritis. At an outpatient neurology evaluation, the 
patient’s whole blood cobalt level was found to be 2,128 
mcg/L (reference <3 mcg/L). She was admitted to 
Thomas Jefferson University Hospital for management 
of progressively worsening symptoms and for hip 
arthroplasty revision evaluation.
The patient’s initial serum cobalt level during hospital-
ization was 1254 mcg/L (reference 0.1-0.4 mcg/L) and the 
whole blood cobalt level was 1997.0 mcg/L (reference 
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Figure 1. Cross-sectional MRI imaging with Metal Artifact Reduction Sequence 
(MARS) Protocol to diminish the signal intensity from metallic objects demonstrates 
local invasion of metallic content into tissue surrounding the joint.
Figure 2. Cross-sectional CT imaging of the patient’s affected hip, demonstrating 
extensive local tissue inflammation extending along the affected joint.
TOXICOLOGY
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ethylendiamine-tetraacetic acid (EDTA), and diethylentri-
amepentaacetic acid (DTPA) for five days in rats, the urinary 
excretion of cobalt was significantly increased by 
glutathione, NAC and DTPA. However, the concentration 
of cobalt in the various tissues of the body was only 
decreased by NAC (liver and spleen) and glutathione 
(spleen)8. EDTA has been the predominant chelator 
administered to humans. In a 2011 study, it provided 
short-term lowering of blood cobalt measurements; 
however, cobalt concentrations rebounded within days. 
This trend occurs because while EDTA binds and removes 
part of the soluble ions present in plasma, there continues 
to be further release of ions from the active surface9.
There is little human evidence available to support 
recommendations for cobalt chelation. The National 
Council on Radiation Protection and Measurements and 
the Radiation Emergency Assistance Center/Training Site 
recommend DTPA for cobalt radionuclide chelation, while 
also stating that DMSA, EDTA, and NAC can be considered. 
For non-radiologic exposure, other sources suggest that 
both NAC and EDTA can be considered, without a definitive 
recommendation10.
There is no conclusive evidence regarding the utility of 
plasmapheresis in cobalt toxicity. In one case of a 22 year 
old male with oral dichromate intoxication, five treatment 
sessions of plasmapheresis significantly lowered his serum 
and urinary chromium concentrations11. This case report 
contributed to the consideration of plasmapheresis as part 
of the management plan in our patient.
Revision surgery appears to be effective in removal of the 
systemic cobalt burden. A 2015 study evaluated blood 
metal ion levels in patients who underwent revision 
surgery for adverse effects due to cobalt and chromium 
debris. There was a decrease in blood cobalt in all patients 
who had unilateral surgery at one year of follow up. In 
some patients with bilateral metal-on-metal hip 
prostheses, cobalt levels remained elevated, but this 
could be attributed to the confounding effect of the 
contralateral metal-on-metal implant12.
KEY POINTS
• Patients with elevated cobalt blood levels after metal-
containing total hip arthroplasties are at risk for 
significant clinical sequelae, including vision and 
hearing loss, peripheral neuropathy, hypothyroidism, 
and cardiomyopathy. 
• Severe gastritis, lactic acidosis and diabetes insipidus 
may also be seen in cobalt toxicity. 
• There is currently no consensus regarding the appropriate 
management of cobalt toxicity. These patients should 
be considered for prosthetic revision to attempt to 
decrease cobalt systemic burden. Chelation with NAC 
and EDTA may be used as adjunctive therapy. Additional 
research is warranted to evaluate the optimal timing of 
revision surgeries and chelation therapy. 
OUTCOME AND FOLLOW-UP
Early in the admission, CT and MRI of the hip demonstrated 
a large area of metallic infiltration (Figure 1) and 
inflammation (Figure 2) in the surrounding tissues. 
Nephrology recommended plasmapheresis to attempt to 
reduce the cobalt burden. On the initial day of plasma-
pheresis, the patient's whole blood cobalt level was 1891 
mcg/L. The next day, the whole blood cobalt level had 
fallen to 1509 mcg/L. Orthopedic surgery performed a left 
hip arthroplasty revision, during which time a significant 
amount of cobalt was found and removed from the joint. 
After the operation, the whole blood cobalt level had 
decreased to 447 mcg/L.
During the hospitalization, plasmapheresis was eventually 
discontinued, as there was little literature to support its use 
in cobalt toxicity and it did not significantly reduce cobalt 
levels. Chelation was recommended, and patient received 
one day of treatment with N-acetylcysteine (NAC) after 
her operation. 
Other complications which arose during the hospital-
ization included lactic acidosis and diabetes insipidus, 
thought to be secondary to cobalt toxicity.  These 
complications, along with the patient’s severe gastritis, 
have not previously been attributed to cobalt toxicity in the 
literature.  However, given the patients few medical 
comorbities and onset corresponding with the elevation in 
cobalt levels, it is likely that they may represent previously 
undescribed complications of cobalt toxicity.  The patient’s 
vision loss was attributed by ophthalmology to optic 
neuropathy and possible retinal toxicity from cobalt.  After 
20 days of hospitalization, the patient’s decreased visual 
acuity and hearing were only mildly improved, her 
peripheral neuropathy persisted, and her thyroid stimulating 
hormone level was 29.47 uIU/mL (nl 0.3-5.0 uIU/mL). The 
whole blood cobalt level after a second left hip irrigation 
prior to discharge was 247 mcg/L. 
DISCUSSION AND MANAGEMENT
A notable element of this case is the accelerated 
development of toxicity after recent revision.  This has been 
found most commonly after shattering of a ceramic joint 
(5,6).  Revisions are complicated by an inability to completely 
remove all the shattered ceramic components, and it is 
believed that retained particles create shearing in the newly 
placed joint that accelerates the release of metal ions.
There is no consensus regarding management of patients 
with systemic symptoms of cobalt toxicity. Clinical 
response to different treatments is not consistently 
documented in current literature. The main objective is to 
eliminate exposure to cobalt and treat systemic symptoms 
supportively, such as with thyroid hormone replacement 
therapy for hypothyroidism, and beta blockers and diuretics 
for cardiomyopathy7. 
In a study evaluating the effects of administration of 
glutathione, NAC, 2,3-dimercaptosuccinic acid (DMSA), 
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